3-(4-氟苄基)-哌啶盐酸盐 | 745817-38-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-(4-氟苄基)-哌啶盐酸盐
• 中文别名: 3-(4-氟苄基)哌啶；3-(4-氟苄基)哌啶盐酸盐
• 英文名称: 3-(4-Fluoro-benzyl)-piperidine; hydrochloride
• 英文别名: 3-(4-Fluorobenzyl)piperidine hydrochloride；3-[(4-fluorophenyl)methyl]piperidine;hydrochloride
• CAS: 745817-38-3
• 化学式: C₁₂H₁₆FN*ClH
• 分子量: 229.725
• InChiKey: MVDNGUDOVPBOPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.79
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-(4-氟苄基)-哌啶盐酸盐 在 盐酸 、 三乙酰氧基硼氢化钠 作用下， 以 1,4-二氧六环 、 1,2-二氯乙烷 为溶剂， 反应 17.0h， 生成
  参考文献：
  名称：

  Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists

  摘要：

  The discovery of novel and selective small molecule antagonists of the CC Chemokine Receptor-3 (CCR3) is presented. Simple conversion from a 4- to 3-benzylpiperidine gave improved selectivity for CCR3 over the serotonin 5HT(2A) receptor. Chiral resolution and exploration of mono- and disubstitution of the N-propylurea resulted in several 3-benzylpiperidine N-propylureas with CCR3 binding IC50S under 5 nM. Data from in vitro calcium mobilization and chemotaxis assays for these compounds ranged from high picomolar to low nanomolar EC(50)s and correlated well with antagonist binding IC(50)s. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.01.059
• 作为产物：
  描述：

  N-BOC-3-羟基哌啶 在 palladium on activated charcoal 盐酸 、 正丁基锂 、 N-甲基吲哚酮 、 四丙基高钌酸铵 、 4 A molecular sieve 、 氢气 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， -78.0 ℃ 、275.79 kPa 条件下， 反应 16.0h， 生成 3-(4-氟苄基)-哌啶盐酸盐
  参考文献：
  名称：

  Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists

  摘要：

  The discovery of novel and selective small molecule antagonists of the CC Chemokine Receptor-3 (CCR3) is presented. Simple conversion from a 4- to 3-benzylpiperidine gave improved selectivity for CCR3 over the serotonin 5HT(2A) receptor. Chiral resolution and exploration of mono- and disubstitution of the N-propylurea resulted in several 3-benzylpiperidine N-propylureas with CCR3 binding IC50S under 5 nM. Data from in vitro calcium mobilization and chemotaxis assays for these compounds ranged from high picomolar to low nanomolar EC(50)s and correlated well with antagonist binding IC(50)s. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.01.059

文献信息

• [EN] SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS<br/>[FR] COMPOSÉS CARBAMATE SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU CANAL POTENTIEL RÉCEPTEUR TRANSITOIRE (TRP)
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014060341A1

  公开（公告）日：2014-04-24

  The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.

  该发明涉及式(I)的化合物及其药学上可接受的盐，其中Y、R1和R3在详细描述和权利要求中有定义。此外，本发明涉及制备和使用式(I)的化合物的方法，以及含有这些化合物的药物组合物。式(I)的化合物是TRPA1通道的拮抗剂，可能对治疗与该通道相关的炎症性疾病和紊乱有用。
• SUBSTITUTED CARBAMATE COMPOUNDS
  申请人：HOFFMANN-LA ROCHE INC

  公开号：US20150218141A1

  公开（公告）日：2015-08-06

  The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.

  本发明涉及式(I)的化合物及其药学上可接受的盐，其中Y、R1和R3在详细说明和权利要求中有定义。此外，本发明还涉及制造和使用式(I)化合物的方法，以及含有这些化合物的制药组合物。式(I)化合物是TRPA1通道的拮抗剂，可能有助于治疗与该通道相关的炎症性疾病和障碍。
• EP2909170A1
  申请人：——

  公开号：EP2909170A1

  公开（公告）日：2015-08-26
• Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists
  作者：Jeffrey G Varnes、Daniel S Gardner、Joseph B Santella、John V Duncia、Melissa Estrella、Paul S Watson、Cheryl M Clark、Soo S Ko、Patricia Welch、Maryanne Covington、Nicole Stowell、Eric Wadman、Paul Davies、Kimberley Solomon、Robert C Newton、George L Trainor、Carl P Decicco、Dean A Wacker

  DOI：10.1016/j.bmcl.2004.01.059

  日期：2004.4

  The discovery of novel and selective small molecule antagonists of the CC Chemokine Receptor-3 (CCR3) is presented. Simple conversion from a 4- to 3-benzylpiperidine gave improved selectivity for CCR3 over the serotonin 5HT(2A) receptor. Chiral resolution and exploration of mono- and disubstitution of the N-propylurea resulted in several 3-benzylpiperidine N-propylureas with CCR3 binding IC50S under 5 nM. Data from in vitro calcium mobilization and chemotaxis assays for these compounds ranged from high picomolar to low nanomolar EC(50)s and correlated well with antagonist binding IC(50)s. (C) 2004 Elsevier Ltd. All rights reserved.